Europe: EMA assessing reports of Guillain-Barre syndrome with AstraZeneca’s #coronavirus vaccine VaxZevria

Astrazeneca, Coronavirus, EU, Europe, Health, Science, Side Effects, Vaccine

“As part of the review of the regular pandemic summary safety reports for Vaxzevria, AstraZeneca’s Covid-19 vaccine, the PRAC is analysing data provided by the marketing authorisation holder on cases of Guillain-Barre syndrome (GBS) [1] reported following vaccination. GBS is an immune system disorder that causes nerve inflammation and can result in pain, numbness, muscle weakness and difficulty walking. GBS was identified during the marketing authorisation process as a possible adverse event requiring specific safety monitoring activities. PRAC has requested the marketing authorisation holder to provide further detailed data, including an analysis of all the reported cases in the context of the next pandemic summary safety report.”

European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC) 3-6 May 2021

1: MayoClinic.org description of Guillain-Barre syndrome 

European Medicines Agency: Carry On Poisoning

 

 

Image courtesy of Doctor JanaDerivative: Momas, CC BY-SA 4.0, via Wikimedia Commons